Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Wen, Wei Xiong ^a,b   Soo, Jaslyn Sian Siu ^a,b   Kwan, Pui Yoke ^a   Hong, Elaine ^a   Khang, Tsung Fei ^b   Mariapun, Shivaani ^a   Lee, Christine Shu Mei ^a   Hasan, Siti Norhidayu ^a   Rajadurai, Pathmanathan ^c   Yip, Cheng Har ^a,c   Mohd Taib, Nur Aishah ^b,d   Teo, Soo Hwang ^a,b,d  

^a CANCER RESEARCH MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c Sime Darby Medical Centre   (Malaysia)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

APOBEC3B; Asian; Breast cancer; Breast cancer risk; Immune response

Indexed keywords

ADULT; APOBEC3B GENE; ARTICLE; BREAST CANCER; CANCER RISK; CELL SUBPOPULATION; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC ASSOCIATION; GERM LINE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INDIAN; MAJOR CLINICAL STUDY; MALAY (PEOPLE); MARKER GENE; MICROARRAY ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; ANTIGEN PRESENTATION; BREAST NEOPLASMS; CASE CONTROL STUDY; COPY NUMBER VARIATION; CROSS-SECTIONAL STUDY; ETHNIC GROUP; ETHNOLOGY; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; IMMUNITY; IMMUNOLOGY; MALAYSIA; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK;

APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; ISOPROTEIN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ADULT; ANTIGEN PRESENTATION; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTIDINE DEAMINASE; DNA COPY NUMBER VARIATIONS; ETHNIC GROUPS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; IMMUNITY; LYMPHOCYTES, TUMOR-INFILTRATING; MALAYSIA; MIDDLE AGED; MINOR HISTOCOMPATIBILITY ANTIGENS; PROTEIN ISOFORMS; RISK; SEQUENCE DELETION;

EID: 84969988140     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0717-1     Document Type: Article

References (28)

1. Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol. 2013;371:1-27.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-21.
3. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45(9):977-83.
4. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970-6.
5. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494(7437):366-70.
6. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007;3(4):e63.
7. Long J, Delahanty RJ, Li G, Gao YT, Lu W, Cai Q, et al. A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst. 2013;105(8):573-9.
8. Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis. 2013;34(10):2240-3.
9. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014;46(5):487-91.
10. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A. 2015;112(9):2841-6.
11. Phuah SY, Lee SY, Kang P, Kang IN, Yoon SY, Thong MK, et al. Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore. PLoS One. 2013;8(8):e73638.
12. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001;98(1):31-6.
13. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-64.
14. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org/. (Accessed on 7 July 2015).
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.
16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article3.
17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-9.
18. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-40.
19. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29(4):365-71.
20. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
21. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-52.
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
23. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
24. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453-7.
25. Mariapun S, Li J, Yip CH, Taib NA, Teo SH. Ethnic differences in mammographic densities: an Asian cross-sectional study. PLoS One. 2015;10(2):e0117568.
26. Caval V, Suspene R, Shapira M, Vartanian JP, Wain-Hobson S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat Commun. 2014;5:5129.
27. Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015;47(9):1067-72.
28. Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128-38.